

## Important Instructions for All OTS Speakers

The Annual OTS Meeting strives to remain at the pinnacle of RNA therapeutics meetings from chemistry and early discovery to clinical trials by carefully selecting highly relevant session topics and outstanding speakers, either by invitation or selected from the submitted abstracts. Consequently, we are expecting our speakers to present their latest (and ideally unpublished) cutting-edge data, thereby providing the audience with new scientific insights and learnings.

In preparing your talk, please follow the OTS Speaking Guidelines:

- **#1. Please avoid extensive introductions** to RNAi, ASOs, mRNAs, CRISPR, etc. and associated mechanisms unless you are describing an entirely new approach. The OTS audience is highly educated as to these common mechanisms. In addition, OTS runs a Sunday morning pre-meeting workshop to bring scientists entering the RNA therapeutics field up to speed.
- **#2.** To allow the audience to appreciate the depth of your science while staying within the time limits, we suggest that you limit/reduce your total number of slides (as opposed to speaking as rapidly as possible).
- **#3.** We strictly enforce **time limits:** maximum **18 minutes for invited talks** (unless otherwise specified) **& 10 minutes for abstract talks.** This allows time for a healthy discussion of your data. Please do not exceed these time constraints. To achieve this, we suggest that you give an in-depth talk on a single topic. For this year's virtual meeting, we are collecting pre-recorded presentations which will be played during the live session and followed by live Q&A.
- **#4. Please include on slide #2 any and all Disclosures, Conflicts of Interest, etc.** as is customary for scientific meetings. If you have none, please just list "None."
- **#5. Please adapt your slides to the 16:9 format** to fully utilize the space on the screen, which will allow the audience to better view your data as compared to the older, smaller 4:3 format.
- **#6. For Speakers from Industry**, please avoid giving a corporate "pipeline" talk lacking key scientific details. While we appreciate that certain experimental details may be proprietary, and we understand that this can be necessary for competitive reasons, **this meeting is about presenting cutting-edge data**, which includes enough experimental details and chemical structures to enable listeners to gain scientific insight from your work. For instance, while not necessarily every structural detail of a novel compound has to be disclosed, we do not want to see a talk where "Compound X" targets "Transcript Y" to treat "a disease in the field of Z". If you are unable to comply with this, you should not present at this year's meeting. In that case, please inform the Session Chair so that a replacement can be sought. Please contact the Organizer and/or Session Chair also if you need further clarification or want to discuss this further.
- **#7. For All Speakers,** please give the audience a sense of how reproducible key proof-of-concept or RNA delivery observations are.